Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndrome

Zealand Pharma's clinical development is running smoothly and the firm has sent a new drug candidate to clinic. Reversely, the resurgence of the Covid-19 pandemic has caused uncertainty regarding the time schedule for the firm's phase III drug Glepaglutide.
Zealand Pharma's CEO Emanuel Dulac. | Photo: Stine Bidstrup/ERH
Zealand Pharma's CEO Emanuel Dulac. | Photo: Stine Bidstrup/ERH

As a biotech firm, Zealand Pharma's first priority during Covid-19 has been to ensure that its research and development program could continue with as few alterations as possible.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading